Objective Heart failure (HF) is common with high associated morbidity and mortality. UK National Institute for Health and ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Background Middle-aged men seem to be particularly susceptible to adverse cardiovascular effects of endurance exercise. The ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.

aBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK Heart failure is a complex clinical syndrome ...

LBBB is linked to electrical abnormalities, causing inefficient heart pumping, dilation, and systolic dysfunction. The study found LBBB associated with increased heart failure risk, surpassing other ...

Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...